Baidu
map
PHARMACOGENOMICS J 润色咨询

PHARMACOGENOMICS JOURNAL

出版年份:2001 年文章数:1056 投稿命中率: 开通期刊会员,数据随心看

出版周期:Bimonthly 自引率:4.0% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=923519, encodeId=e1b29235198b, content=已被下调为3区, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6772357323, createdName=122c3e01m19(暂无昵称), createdTime=Sun Feb 07 18:20:46 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855638, encodeId=7ea4855638a9, content=审稿速度:10.0<br>经验分享:这个杂志超级拖,文章被压了近八个月才送审,最后仅送了一个审稿人,修回后被拒,说是文章概念不新。本来就是写的一篇小综述,被拖了这么久,再新的概念都旧了。这个杂志神坑,希望能帮助大家避开。当然如果你时间多且完全不在意,也可以踩踩坑 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08165414055, createdName=ms9532643183630560, createdTime=Mon Dec 09 09:21:10 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574226, encodeId=372c5e422649, content=请问,后来的状态有什么变化吗?还是说under consideration就是under review的意思呀?谢谢<span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 08:48:00 发表: 2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01175151911, createdName=15736875548_88179330, createdTime=Wed Jul 31 00:00:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571171, encodeId=a9545e1171c3, content=我打算投药物基因组,会不会很热门呢 <span class="quote">palexander 2019-04-23 发表::<br>研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱</span><span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 发表:: 研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee42570897, createdName=930481735_75285775, createdTime=Sun May 19 00:00:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569913, encodeId=20035699133d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27d381873, createdName=palexander, createdTime=Tue Apr 23 08:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532053, encodeId=30f353205381, content=投了篇meta一审一个月多拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/q7Hn9JgEyWzxibdfH1iayiaupBicIqfdlT7FnzRk2rID6AicJHZnaVMgYOzheIEJLPqgA2pHWRyP6xd3yabKo46AdVw/132, createdBy=d2071616805, createdName=helpwl, createdTime=Thu Jan 19 12:57:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=478274, encodeId=74774e827475, content=偏重的研究方向:基因组学;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=455, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=null, createdTime=Wed Jun 29 15:29:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473962, encodeId=79e14e39624e, content=不易啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=毛毛, createdTime=Sat Feb 26 20:25:00 CST 2011, time=2011-02-26, status=1, ipAttribution=)]
    2021-02-07 122c3e01m19(暂无昵称)

    已被下调为3区

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=923519, encodeId=e1b29235198b, content=已被下调为3区, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6772357323, createdName=122c3e01m19(暂无昵称), createdTime=Sun Feb 07 18:20:46 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855638, encodeId=7ea4855638a9, content=审稿速度:10.0<br>经验分享:这个杂志超级拖,文章被压了近八个月才送审,最后仅送了一个审稿人,修回后被拒,说是文章概念不新。本来就是写的一篇小综述,被拖了这么久,再新的概念都旧了。这个杂志神坑,希望能帮助大家避开。当然如果你时间多且完全不在意,也可以踩踩坑 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08165414055, createdName=ms9532643183630560, createdTime=Mon Dec 09 09:21:10 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574226, encodeId=372c5e422649, content=请问,后来的状态有什么变化吗?还是说under consideration就是under review的意思呀?谢谢<span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 08:48:00 发表: 2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01175151911, createdName=15736875548_88179330, createdTime=Wed Jul 31 00:00:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571171, encodeId=a9545e1171c3, content=我打算投药物基因组,会不会很热门呢 <span class="quote">palexander 2019-04-23 发表::<br>研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱</span><span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 发表:: 研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee42570897, createdName=930481735_75285775, createdTime=Sun May 19 00:00:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569913, encodeId=20035699133d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27d381873, createdName=palexander, createdTime=Tue Apr 23 08:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532053, encodeId=30f353205381, content=投了篇meta一审一个月多拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/q7Hn9JgEyWzxibdfH1iayiaupBicIqfdlT7FnzRk2rID6AicJHZnaVMgYOzheIEJLPqgA2pHWRyP6xd3yabKo46AdVw/132, createdBy=d2071616805, createdName=helpwl, createdTime=Thu Jan 19 12:57:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=478274, encodeId=74774e827475, content=偏重的研究方向:基因组学;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=455, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=null, createdTime=Wed Jun 29 15:29:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473962, encodeId=79e14e39624e, content=不易啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=毛毛, createdTime=Sat Feb 26 20:25:00 CST 2011, time=2011-02-26, status=1, ipAttribution=)]
    2019-12-09 ms9532643183630560

    审稿速度:10.0
    经验分享:这个杂志超级拖,文章被压了近八个月才送审,最后仅送了一个审稿人,修回后被拒,说是文章概念不新。本来就是写的一篇小综述,被拖了这么久,再新的概念都旧了。这个杂志神坑,希望能帮助大家避开。当然如果你时间多且完全不在意,也可以踩踩坑

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=923519, encodeId=e1b29235198b, content=已被下调为3区, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6772357323, createdName=122c3e01m19(暂无昵称), createdTime=Sun Feb 07 18:20:46 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855638, encodeId=7ea4855638a9, content=审稿速度:10.0<br>经验分享:这个杂志超级拖,文章被压了近八个月才送审,最后仅送了一个审稿人,修回后被拒,说是文章概念不新。本来就是写的一篇小综述,被拖了这么久,再新的概念都旧了。这个杂志神坑,希望能帮助大家避开。当然如果你时间多且完全不在意,也可以踩踩坑 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08165414055, createdName=ms9532643183630560, createdTime=Mon Dec 09 09:21:10 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574226, encodeId=372c5e422649, content=请问,后来的状态有什么变化吗?还是说under consideration就是under review的意思呀?谢谢<span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 08:48:00 发表: 2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01175151911, createdName=15736875548_88179330, createdTime=Wed Jul 31 00:00:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571171, encodeId=a9545e1171c3, content=我打算投药物基因组,会不会很热门呢 <span class="quote">palexander 2019-04-23 发表::<br>研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱</span><span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 发表:: 研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee42570897, createdName=930481735_75285775, createdTime=Sun May 19 00:00:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569913, encodeId=20035699133d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27d381873, createdName=palexander, createdTime=Tue Apr 23 08:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532053, encodeId=30f353205381, content=投了篇meta一审一个月多拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/q7Hn9JgEyWzxibdfH1iayiaupBicIqfdlT7FnzRk2rID6AicJHZnaVMgYOzheIEJLPqgA2pHWRyP6xd3yabKo46AdVw/132, createdBy=d2071616805, createdName=helpwl, createdTime=Thu Jan 19 12:57:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=478274, encodeId=74774e827475, content=偏重的研究方向:基因组学;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=455, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=null, createdTime=Wed Jun 29 15:29:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473962, encodeId=79e14e39624e, content=不易啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=毛毛, createdTime=Sat Feb 26 20:25:00 CST 2011, time=2011-02-26, status=1, ipAttribution=)]
    2019-07-31 15736875548_88179330

    请问,后来的状态有什么变化吗?还是说under consideration就是under review的意思呀?谢谢palexander 2019-04-23 08:48:00 发表:
    2018-11-02投稿,11-20under consideration,至今状态没有改变...
    编辑部在03-27还专门发了一个致歉信...可爱

    palexander 2019-04-23 08:48:00 发表: 2018-11-02投稿,11-20under consideration,至今状态没有改变...
    编辑部在03-27还专门发了一个致歉信...可爱

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=923519, encodeId=e1b29235198b, content=已被下调为3区, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6772357323, createdName=122c3e01m19(暂无昵称), createdTime=Sun Feb 07 18:20:46 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855638, encodeId=7ea4855638a9, content=审稿速度:10.0<br>经验分享:这个杂志超级拖,文章被压了近八个月才送审,最后仅送了一个审稿人,修回后被拒,说是文章概念不新。本来就是写的一篇小综述,被拖了这么久,再新的概念都旧了。这个杂志神坑,希望能帮助大家避开。当然如果你时间多且完全不在意,也可以踩踩坑 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08165414055, createdName=ms9532643183630560, createdTime=Mon Dec 09 09:21:10 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574226, encodeId=372c5e422649, content=请问,后来的状态有什么变化吗?还是说under consideration就是under review的意思呀?谢谢<span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 08:48:00 发表: 2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01175151911, createdName=15736875548_88179330, createdTime=Wed Jul 31 00:00:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571171, encodeId=a9545e1171c3, content=我打算投药物基因组,会不会很热门呢 <span class="quote">palexander 2019-04-23 发表::<br>研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱</span><span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 发表:: 研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee42570897, createdName=930481735_75285775, createdTime=Sun May 19 00:00:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569913, encodeId=20035699133d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27d381873, createdName=palexander, createdTime=Tue Apr 23 08:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532053, encodeId=30f353205381, content=投了篇meta一审一个月多拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/q7Hn9JgEyWzxibdfH1iayiaupBicIqfdlT7FnzRk2rID6AicJHZnaVMgYOzheIEJLPqgA2pHWRyP6xd3yabKo46AdVw/132, createdBy=d2071616805, createdName=helpwl, createdTime=Thu Jan 19 12:57:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=478274, encodeId=74774e827475, content=偏重的研究方向:基因组学;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=455, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=null, createdTime=Wed Jun 29 15:29:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473962, encodeId=79e14e39624e, content=不易啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=毛毛, createdTime=Sat Feb 26 20:25:00 CST 2011, time=2011-02-26, status=1, ipAttribution=)]
    2019-05-19 930481735_75285775

    我打算投药物基因组,会不会很热门呢 palexander 2019-04-23 发表::
    研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱
    palexander 2019-04-23 08:48:00 发表:
    2018-11-02投稿,11-20under consideration,至今状态没有改变...
    编辑部在03-27还专门发了一个致歉信...可爱

    palexander 2019-04-23 发表:: 研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=923519, encodeId=e1b29235198b, content=已被下调为3区, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6772357323, createdName=122c3e01m19(暂无昵称), createdTime=Sun Feb 07 18:20:46 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855638, encodeId=7ea4855638a9, content=审稿速度:10.0<br>经验分享:这个杂志超级拖,文章被压了近八个月才送审,最后仅送了一个审稿人,修回后被拒,说是文章概念不新。本来就是写的一篇小综述,被拖了这么久,再新的概念都旧了。这个杂志神坑,希望能帮助大家避开。当然如果你时间多且完全不在意,也可以踩踩坑 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08165414055, createdName=ms9532643183630560, createdTime=Mon Dec 09 09:21:10 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574226, encodeId=372c5e422649, content=请问,后来的状态有什么变化吗?还是说under consideration就是under review的意思呀?谢谢<span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 08:48:00 发表: 2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01175151911, createdName=15736875548_88179330, createdTime=Wed Jul 31 00:00:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571171, encodeId=a9545e1171c3, content=我打算投药物基因组,会不会很热门呢 <span class="quote">palexander 2019-04-23 发表::<br>研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱</span><span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 发表:: 研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee42570897, createdName=930481735_75285775, createdTime=Sun May 19 00:00:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569913, encodeId=20035699133d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27d381873, createdName=palexander, createdTime=Tue Apr 23 08:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532053, encodeId=30f353205381, content=投了篇meta一审一个月多拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/q7Hn9JgEyWzxibdfH1iayiaupBicIqfdlT7FnzRk2rID6AicJHZnaVMgYOzheIEJLPqgA2pHWRyP6xd3yabKo46AdVw/132, createdBy=d2071616805, createdName=helpwl, createdTime=Thu Jan 19 12:57:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=478274, encodeId=74774e827475, content=偏重的研究方向:基因组学;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=455, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=null, createdTime=Wed Jun 29 15:29:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473962, encodeId=79e14e39624e, content=不易啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=毛毛, createdTime=Sat Feb 26 20:25:00 CST 2011, time=2011-02-26, status=1, ipAttribution=)]
    2019-04-23 palexander

    审稿速度:6.0 | 投稿命中率:50.0
    经验分享:2018-11-02投稿,11-20under consideration,至今状态没有改变...
    编辑部在03-27还专门发了一个致歉信...可爱

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=923519, encodeId=e1b29235198b, content=已被下调为3区, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6772357323, createdName=122c3e01m19(暂无昵称), createdTime=Sun Feb 07 18:20:46 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855638, encodeId=7ea4855638a9, content=审稿速度:10.0<br>经验分享:这个杂志超级拖,文章被压了近八个月才送审,最后仅送了一个审稿人,修回后被拒,说是文章概念不新。本来就是写的一篇小综述,被拖了这么久,再新的概念都旧了。这个杂志神坑,希望能帮助大家避开。当然如果你时间多且完全不在意,也可以踩踩坑 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08165414055, createdName=ms9532643183630560, createdTime=Mon Dec 09 09:21:10 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574226, encodeId=372c5e422649, content=请问,后来的状态有什么变化吗?还是说under consideration就是under review的意思呀?谢谢<span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 08:48:00 发表: 2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01175151911, createdName=15736875548_88179330, createdTime=Wed Jul 31 00:00:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571171, encodeId=a9545e1171c3, content=我打算投药物基因组,会不会很热门呢 <span class="quote">palexander 2019-04-23 发表::<br>研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱</span><span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 发表:: 研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee42570897, createdName=930481735_75285775, createdTime=Sun May 19 00:00:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569913, encodeId=20035699133d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27d381873, createdName=palexander, createdTime=Tue Apr 23 08:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532053, encodeId=30f353205381, content=投了篇meta一审一个月多拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/q7Hn9JgEyWzxibdfH1iayiaupBicIqfdlT7FnzRk2rID6AicJHZnaVMgYOzheIEJLPqgA2pHWRyP6xd3yabKo46AdVw/132, createdBy=d2071616805, createdName=helpwl, createdTime=Thu Jan 19 12:57:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=478274, encodeId=74774e827475, content=偏重的研究方向:基因组学;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=455, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=null, createdTime=Wed Jun 29 15:29:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473962, encodeId=79e14e39624e, content=不易啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=毛毛, createdTime=Sat Feb 26 20:25:00 CST 2011, time=2011-02-26, status=1, ipAttribution=)]
    2017-01-19 helpwl

    投了篇meta一审一个月多拒稿

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=923519, encodeId=e1b29235198b, content=已被下调为3区, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6772357323, createdName=122c3e01m19(暂无昵称), createdTime=Sun Feb 07 18:20:46 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855638, encodeId=7ea4855638a9, content=审稿速度:10.0<br>经验分享:这个杂志超级拖,文章被压了近八个月才送审,最后仅送了一个审稿人,修回后被拒,说是文章概念不新。本来就是写的一篇小综述,被拖了这么久,再新的概念都旧了。这个杂志神坑,希望能帮助大家避开。当然如果你时间多且完全不在意,也可以踩踩坑 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08165414055, createdName=ms9532643183630560, createdTime=Mon Dec 09 09:21:10 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574226, encodeId=372c5e422649, content=请问,后来的状态有什么变化吗?还是说under consideration就是under review的意思呀?谢谢<span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 08:48:00 发表: 2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01175151911, createdName=15736875548_88179330, createdTime=Wed Jul 31 00:00:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571171, encodeId=a9545e1171c3, content=我打算投药物基因组,会不会很热门呢 <span class="quote">palexander 2019-04-23 发表::<br>研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱</span><span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 发表:: 研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee42570897, createdName=930481735_75285775, createdTime=Sun May 19 00:00:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569913, encodeId=20035699133d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27d381873, createdName=palexander, createdTime=Tue Apr 23 08:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532053, encodeId=30f353205381, content=投了篇meta一审一个月多拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/q7Hn9JgEyWzxibdfH1iayiaupBicIqfdlT7FnzRk2rID6AicJHZnaVMgYOzheIEJLPqgA2pHWRyP6xd3yabKo46AdVw/132, createdBy=d2071616805, createdName=helpwl, createdTime=Thu Jan 19 12:57:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=478274, encodeId=74774e827475, content=偏重的研究方向:基因组学;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=455, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=null, createdTime=Wed Jun 29 15:29:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473962, encodeId=79e14e39624e, content=不易啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=毛毛, createdTime=Sat Feb 26 20:25:00 CST 2011, time=2011-02-26, status=1, ipAttribution=)]
    2011-06-29 匿名用户

    偏重的研究方向:基因组学;

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=923519, encodeId=e1b29235198b, content=已被下调为3区, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6772357323, createdName=122c3e01m19(暂无昵称), createdTime=Sun Feb 07 18:20:46 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855638, encodeId=7ea4855638a9, content=审稿速度:10.0<br>经验分享:这个杂志超级拖,文章被压了近八个月才送审,最后仅送了一个审稿人,修回后被拒,说是文章概念不新。本来就是写的一篇小综述,被拖了这么久,再新的概念都旧了。这个杂志神坑,希望能帮助大家避开。当然如果你时间多且完全不在意,也可以踩踩坑 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08165414055, createdName=ms9532643183630560, createdTime=Mon Dec 09 09:21:10 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574226, encodeId=372c5e422649, content=请问,后来的状态有什么变化吗?还是说under consideration就是under review的意思呀?谢谢<span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 08:48:00 发表: 2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01175151911, createdName=15736875548_88179330, createdTime=Wed Jul 31 00:00:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571171, encodeId=a9545e1171c3, content=我打算投药物基因组,会不会很热门呢 <span class="quote">palexander 2019-04-23 发表::<br>研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱</span><span class="quote">palexander 2019-04-23 08:48:00 发表:<br>2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱</span>, beContent=palexander 2019-04-23 发表:: 研究方向:药物基因组学;; 接收率:约50% 审稿时间:约6个月 2018-11-02投稿,11-20under consideration,至今状态没有改变... 编辑部在03-27还专门发了一个致歉信...可爱, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee42570897, createdName=930481735_75285775, createdTime=Sun May 19 00:00:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569913, encodeId=20035699133d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2018-11-02投稿,11-20under consideration,至今状态没有改变... <br> 编辑部在03-27还专门发了一个致歉信...可爱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27d381873, createdName=palexander, createdTime=Tue Apr 23 08:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532053, encodeId=30f353205381, content=投了篇meta一审一个月多拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/q7Hn9JgEyWzxibdfH1iayiaupBicIqfdlT7FnzRk2rID6AicJHZnaVMgYOzheIEJLPqgA2pHWRyP6xd3yabKo46AdVw/132, createdBy=d2071616805, createdName=helpwl, createdTime=Thu Jan 19 12:57:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=478274, encodeId=74774e827475, content=偏重的研究方向:基因组学;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=455, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=null, createdTime=Wed Jun 29 15:29:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473962, encodeId=79e14e39624e, content=不易啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=530, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=毛毛, createdTime=Sat Feb 26 20:25:00 CST 2011, time=2011-02-26, status=1, ipAttribution=)]
    2011-02-26 毛毛

    不易啊

    0

共8条页码: 1/1页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map